Cuna G R, Calciati A, Strada M R, Bumma C, Campio L
Tumori. 1978 Apr 30;64(2):143-9. doi: 10.1177/030089167806400204.
The results of controlled clinical trial that used high doses of medroxyprogesterone acetate (MPA) in the treatment of metastatic breast cancer are reported. Two treatment reigmens were used: regimen A, 500 mg daily with a total dose of 30 g; regimen B, 1,000 mg daily with a total dose of 60 g. The overall response rates were similar, with no statistically significant difference between the two treated groups. Regimen A (lower dosage group) reached a remission rate of 44%, whereas regimen B (higher dosage group) had a remission rate of 41%. The mean duration of response was 8 months with regimen A and 9 months with regimen B. The advantages of the lower dosage regimen as opposed to the higher dosage regimen of MPA in the treatment of advanced breast cancer are discussed.
报告了使用高剂量醋酸甲羟孕酮（MPA）治疗转移性乳腺癌的对照临床试验结果。采用了两种治疗方案：方案A，每日500毫克，总剂量30克；方案B，每日1000毫克，总剂量60克。总体缓解率相似，两个治疗组之间无统计学显著差异。方案A（低剂量组）的缓解率为44%，而方案B（高剂量组）的缓解率为41%。方案A的平均缓解持续时间为8个月，方案B为9个月。讨论了MPA低剂量方案相对于高剂量方案在治疗晚期乳腺癌方面的优势。
